转移性非小细胞肺癌的一线治疗：最新的靶向治疗和免疫治疗方法
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches.
作者信息
Bauml Joshua, Knepley Christina
机构信息
Penn Medicine, Philadelphia.
出版信息
J Adv Pract Oncol. 2020 Apr;11(3):260-265. doi: 10.6004/jadpro.2020.11.3.9. Epub 2020 Apr 1.
Abstract
At JADPRO Live 2019, Joshua Bauml, MD, and Christina Knepley, CRNP, discussed how to devise treatment plans for patients with metastatic non-small cell lung cancer, including using biomarkers to guide treatment selection, understanding clinical data supporting the use of targeted and immune checkpoint inhibitor therapies, and managing adverse events.
摘要
在2019年JADPRO直播活动中，医学博士约书亚·鲍姆尔和临床注册护士从业者克里斯蒂娜·克内普利讨论了如何为转移性非小细胞肺癌患者制定治疗方案，包括利用生物标志物指导治疗选择、理解支持使用靶向治疗和免疫检查点抑制剂疗法的临床数据，以及管理不良事件。
相似文献
1
First-Line Therapy for Metastatic Non-Small Cell Lung Cancer: State-of-the-Art Targeted Therapy and Immunotherapy Approaches.转移性非小细胞肺癌的一线治疗：最新的靶向治疗和免疫治疗方法
J Adv Pract Oncol. 2020 Apr;11(3):260-265. doi: 10.6004/jadpro.2020.11.3.9. Epub 2020 Apr 1.
2
Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.免疫检查点阻断作为非小细胞肺癌的潜在治疗靶点。
Expert Opin Biol Ther. 2016 Oct;16(10):1209-23. doi: 10.1080/14712598.2016.1214265. Epub 2016 Aug 5.
3
Updating the Targeted Therapy Paradigm for Patients With Metastatic NSCLC.更新转移性非小细胞肺癌患者的靶向治疗模式。
J Adv Pract Oncol. 2023 Apr;14(3):241-247. doi: 10.6004/jadpro.2023.14.3.12. Epub 2023 Apr 1.
4
Advancing Precision-Targeted Treatment for Patients With Metastatic Non-Small Cell Lung Cancer.推进转移性非小细胞肺癌患者的精准靶向治疗。
J Adv Pract Oncol. 2024 Apr;15(3):170-176. doi: 10.6004/jadpro.2024.15.3.7. Epub 2024 Apr 1.
5
Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: A Review.局部晚期和转移性非小细胞肺癌的系统治疗：综述。
JAMA. 2019 Aug 27;322(8):764-774. doi: 10.1001/jama.2019.11058.
6
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.免疫治疗与非小细胞肺癌患者生存及免疫相关生物标志物的相关性：一项荟萃分析和个体患者水平分析。
JAMA Netw Open. 2019 Jul 3;2(7):e196879. doi: 10.1001/jamanetworkopen.2019.6879.
7
Biomarkers for Immunotherapy.免疫治疗的生物标志物。
Thorac Surg Clin. 2020 May;30(2):207-214. doi: 10.1016/j.thorsurg.2020.01.010.
8
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer.抗PD-1/PD-L1疗法在非小细胞肺癌中的不良反应
Front Oncol. 2020 Sep 17;10:554313. doi: 10.3389/fonc.2020.554313. eCollection 2020.
9
Immunotherapy for the Treatment of Triple-Negative Breast Cancer.三阴性乳腺癌治疗的免疫疗法
J Adv Pract Oncol. 2022 Apr;13(3):298-301. doi: 10.6004/jadpro.2022.13.3.23. Epub 2022 May 23.
10
Immune checkpoint inhibitors in advanced non-small cell lung cancer.免疫检查点抑制剂在晚期非小细胞肺癌中的应用。
Cancer. 2018 Jan 15;124(2):248-261. doi: 10.1002/cncr.31105. Epub 2017 Dec 6.
引用本文的文献
1
Immune Landscape and Classification in Lung Adenocarcinoma Based on a Novel Cell Cycle Checkpoints Related Signature for Predicting Prognosis and Therapeutic Response.基于一种新型细胞周期检查点相关特征的肺腺癌免疫景观与分类，用于预测预后和治疗反应
Front Genet. 2022 May 11;13:908104. doi: 10.3389/fgene.2022.908104. eCollection 2022.
本文引用的文献
1
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。
Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.
2
Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study.更新的疗效和安全性数据以及 EML4-ALK 融合变体对全球 III 期 ALEX 研究中未经治疗的 ALK 阳性晚期非小细胞肺癌中阿来替尼疗效的影响。
J Thorac Oncol. 2019 Jul;14(7):1233-1243. doi: 10.1016/j.jtho.2019.03.007. Epub 2019 Mar 20.
3
Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater.KEYNOTE-024 更新分析：PD-L1 肿瘤比例评分≥50%的晚期非小细胞肺癌的帕博利珠单抗对比铂类化疗
J Clin Oncol. 2019 Mar 1;37(7):537-546. doi: 10.1200/JCO.18.00149. Epub 2019 Jan 8.
4
Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗用于鳞状非小细胞肺癌。
N Engl J Med. 2018 Nov 22;379(21):2040-2051. doi: 10.1056/NEJMoa1810865. Epub 2018 Sep 25.
5
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。
N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.
6
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer.帕博利珠单抗联合化疗治疗转移性非小细胞肺癌。
N Engl J Med. 2018 May 31;378(22):2078-2092. doi: 10.1056/NEJMoa1801005. Epub 2018 Apr 16.
7
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.奥希替尼治疗未经治疗的 EGFR 突变型晚期非小细胞肺癌。
N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18.
8
Epidermal growth factor receptor mutation subtypes and geographical distribution among Indian non-small cell lung cancer patients.印度非小细胞肺癌患者中表皮生长因子受体突变亚型及地理分布
Indian J Cancer. 2013 Apr-Jun;50(2):107-11. doi: 10.4103/0019-509X.117023.
Zotero 插件